Salesforce Friends ...
Health Care: Drugs
Exelixis Inc. (EXEL: NASDAQ)
$4.52 0.04 | 1.01%
06/04/12 - 12:30 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 289.64M | 185.04M | 151.76M | 117.86M |
| Cost of Sales | -6.82M | -10.54M | -12.60M | -13.23M |
| Gross Operating Profit | 296.46M | 195.59M | 164.35M | 131.09M |
| Selling, General, and Administrative Expenses | 33.13M | 33.02M | 38.96M | 36.89M |
| Research & Development | 156.84M | 210.68M | 234.70M | 257.39M |
| Operating Income before D & A (EBITDA) | 106.49M | -48.11M | -109.31M | -163.20M |
| Depreciation & Amortization | 6.82M | 10.54M | 12.60M | 13.23M |
| Interest Income | 1.46M | 138.00K | 1.51M | 5.94M |
| Other Income - Net | 2.25M | 8.20M | -7.77M | 0.00 |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | 93.25M | -83.06M | -128.17M | -168.81M |
| Interest Expense | 16.26M | 9.34M | 12.67M | 6.76M |
| Pre-Tax Income | 76.99M | -92.40M | -140.84M | -175.57M |
| Income Taxes | 1.30M | -72.00K | -1.29M | 0.00 |
| Minority Interest | 0.00 | 0.00 | -4.34M | -12.72M |
| Net Income From Continuing Operations | 75.70M | -92.33M | -135.22M | -162.85M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | 75.70M | -92.33M | -135.22M | -162.85M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | 75.70M | -92.33M | -135.22M | -162.85M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
85.83M | -59.59M | -135.22M | -164.53M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | 75.70M | -92.33M | -135.22M | -162.85M |
| Basic EPS from Continuing Ops. | 0.60 | -0.85 | -1.26 | -1.54 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | 0.60 | -0.85 | -1.26 | -1.54 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | 0.60 | -0.85 | -1.26 | -1.54 |
| Basic Normalized Net Income/Share | 0.68 | -0.55 | -1.26 | -1.56 |
| EPS fr Continuing Ops. | 0.58 | -0.85 | -1.26 | -1.54 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | 0.58 | -0.85 | -1.26 | -1.54 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | 0.58 | -0.85 | -1.26 | -1.54 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0.66 | -0.55 | -1.26 | -1.56 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with EXEL
- Portfolio NameUser Type
- Contributor10 Stocks That Could Rise i...
- Contributor10 Biotech Stocks Loved and...
- Contributor10 Biotech Trades for Secon...
- UserMy Portfolio
- ContributorCancer Drug Stocks to Trade...
- Userbarry216 Portfolio 1
- UserSUPRATRADE HOT STOCKS (BUY ...
- UserASCO 2010
- UserBartwaldon Portfolio 1
- UserPART 3 JPMorgan 28th Annual...
Latest EXEL Headlines from TheStreet
- ASCO 2012 Live Blog -- Sunday 06.03.12 | 07:06 am
- ASCO 2012 Live Blog -- Saturday 06.02.12 | 07:06 am
- Exelixis' Management Presents At Bank Of America Merrill Lynch 2012 Health Care Conference (Transcript) 05.17.12 | 06:05 pm
- ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- Exelixis' Management Presents At Deutsche Bank Securities Annual Health Care Conference (Transcript) 05.09.12 | 08:05 pm
- Friday's Top 10 Articles, Videos on TheStreet 05.04.12 | 01:05 pm
- Biotech Stock Mailbag: Exelixis, Protalix, Arena 05.04.12 | 07:05 am
- Exelixis's CEO Discusses Q1 2012 Results - Earnings Call Transcript 05.03.12 | 10:05 pm
- 10 Stocks That Could Rise in Market Decline 04.10.12 | 07:04 am
Press Releases for EXEL
- Cabozantinib Meets Primary Endpoint Of Progression Free Survival In Phase 3 Pivotal Trial In Medullary Thyroid Cancer - Business Wire 06.04.12 | 12:06 pm
- Cabozantinib Demonstrates Evidence Of Anti-Tumor Effects In Heavily Pretreated Patients With Hepatocellular Carcinoma - Business Wire 06.02.12 | 06:06 pm
- Cabozantinib Demonstrates Encouraging Activity In Patients With Heavily Pretreated Metastatic Renal Cell Carcinoma - Business Wire 06.02.12 | 05:06 pm
- Exelixis Announces June 6th Webcast Of Presentation At The Goldman Sachs 33rd Annual Global Healthcare Conference - Business Wire 05.31.12 | 05:05 pm
- Exelixis Initiates COMET-1 Pivotal Trial Focused On Overall Survival In Men With Advanced Prostate Cancer - Business Wire 05.30.12 | 06:05 am
- Exelixis Completes Submission Of New Drug Application For Cabozantinib For The Treatment Of Medullary Thyroid Cancer - Business Wire 05.30.12 | 06:05 am
- Reminder: Exelixis Announces Data Presentations, Webcast Of Investor Briefing In Conjunction With 2012 ASCO Annual Meeting - Business Wire 05.16.12 | 06:05 am
- Exelixis Expands The Cabozantinib Development Program Through NCI-CTEP Collaboration - Business Wire 05.03.12 | 06:05 am
- Exelixis Announces May 8th Webcast Of Presentation At The Deutsche Bank Securities 37th Annual Health Care Conference - Business Wire 05.02.12 | 04:05 pm
- Exelixis Announces May 3rd Webcast Of First Quarter 2012 Financial Results Conference Call - Business Wire 04.19.12 | 04:04 pm
Partner Headlines for EXEL
- Cabozantinib Demonstrates Evidence of Anti-Tumor Effects in Heavily Pretreated Patients with Hepatocellular Carcinoma - Benzinga 06.02.12 | 06:06 pm
- Biotech Stocks To Watch In 2012 - Seeking Alpha 02.06.12 | 09:02 am
- 5 Biotech Stocks That Could Double - Seeking Alpha 02.01.12 | 07:02 am
- UPDATE: Piper Jaffray Downgrades Exelixis to Neutral - Benzinga 11.01.11 | 09:11 am
- Notable Put Options Activity in Exelixis - Benzinga 10.28.11 | 01:10 pm
- 3 Biotech Takeover/LBO Targets With Bullish Short Trends - Seeking Alpha 10.26.11 | 09:10 am
- 7 Possible Biotech Takeover Targets - Seeking Alpha 09.18.11 | 08:09 am
- Biotech Gem Exelixis Is Compelling Only for the Long Term - Seeking Alpha 08.19.11 | 05:08 pm
- 5 Biotech Takeover / LBO Targets With Bullish Short Trends - Seeking Alpha 07.15.11 | 07:07 pm
- Exelixis extends timeline for thyroid cancer data - Reuters 07.06.11 | 04:07 pm
